EGFR and central nervous system cancer: The presence of EGFR in EVs was first described in 2007 by Al-Nedawi et al. This study provided evidence that glioma cells expressing the truncated form of EGFR, known as EGFRvIII, can transfer it via EVs to cells lacking this form, leading to the activation of downstream signaling pathways[154].